NYSEMKT: PHGEBiomx Inc Stock
$4.71-0.18 (-3.68%)
Updated Mar 26, 2026
PHGE Price
$4.71
Fair Value Price
N/A
Market Cap
$7.51M
52 Week Low
$1.50
52 Week High
$14.71
P/E
-0.21x
P/B
-5.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$36.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-5.44
Operating Cash Flow
-$26M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PHGE Overview
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHGE's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PHGE
Ranked#446 of 466
Ranked#446 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $189.15 | A | |
| $32.80 | A | |
| $16.31 | A |
Be the first to know about important PHGE news, forecast changes, insider trades & much more!
PHGE News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHGE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHGE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PHGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PHGE due diligence checks available for Premium users.
Valuation
PHGE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
24.99x
Market
31.07x
PHGE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5.77x
Industry
4.64x
PHGE's financial health
Profit margin
Revenue
$0.0
Net Income
-$59.1M
Profit Margin
0%
PHGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.8M
Liabilities
$7.1M
Debt to equity
-5.44
PHGE's short-term liabilities ($6.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHGE's short-term assets ($5.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHGE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
$1.0k
Financing
$1.3M
PHGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHGE vs Biotech Stocks
Biomx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.